PT1592423E - Terapia de combinação de zd6474 com 5-fu e/ou cpt-11 - Google Patents

Terapia de combinação de zd6474 com 5-fu e/ou cpt-11 Download PDF

Info

Publication number
PT1592423E
PT1592423E PT04710081T PT04710081T PT1592423E PT 1592423 E PT1592423 E PT 1592423E PT 04710081 T PT04710081 T PT 04710081T PT 04710081 T PT04710081 T PT 04710081T PT 1592423 E PT1592423 E PT 1592423E
Authority
PT
Portugal
Prior art keywords
cpt
combination
combination therapy
cancer
antiangiogenic
Prior art date
Application number
PT04710081T
Other languages
English (en)
Inventor
Stephen Robert Wedge
Anderson Joseph Ryan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0303289A external-priority patent/GB0303289D0/en
Priority claimed from GB0314100A external-priority patent/GB0314100D0/en
Priority claimed from GB0316184A external-priority patent/GB0316184D0/en
Priority claimed from GB0318311A external-priority patent/GB0318311D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1592423E publication Critical patent/PT1592423E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT04710081T 2003-02-13 2004-02-11 Terapia de combinação de zd6474 com 5-fu e/ou cpt-11 PT1592423E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0303289A GB0303289D0 (en) 2003-02-13 2003-02-13 Combination therapy
GB0314100A GB0314100D0 (en) 2003-06-18 2003-06-18 Combination therapy
GB0316184A GB0316184D0 (en) 2003-07-10 2003-07-10 Combination therapy
GB0318311A GB0318311D0 (en) 2003-08-05 2003-08-05 Combination therapy

Publications (1)

Publication Number Publication Date
PT1592423E true PT1592423E (pt) 2011-06-16

Family

ID=32872851

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04710081T PT1592423E (pt) 2003-02-13 2004-02-11 Terapia de combinação de zd6474 com 5-fu e/ou cpt-11

Country Status (18)

Country Link
US (4) US20060142316A1 (pt)
EP (1) EP1592423B1 (pt)
JP (3) JP2006517575A (pt)
KR (2) KR20110006699A (pt)
AT (1) ATE506062T1 (pt)
AU (1) AU2004212255B2 (pt)
CA (1) CA2514227C (pt)
CY (1) CY1111565T1 (pt)
DE (1) DE602004032310D1 (pt)
DK (1) DK1592423T3 (pt)
HK (1) HK1084032A1 (pt)
IL (1) IL169702A (pt)
MX (1) MXPA05008583A (pt)
NO (1) NO331486B1 (pt)
NZ (1) NZ541297A (pt)
PT (1) PT1592423E (pt)
SI (1) SI1592423T1 (pt)
WO (1) WO2004071397A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398120T1 (de) 1999-11-05 2008-07-15 Astrazeneca Ab Neue quinazolin-derivate
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
US7462623B2 (en) 2002-11-04 2008-12-09 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
EP1592423B1 (en) * 2003-02-13 2011-04-20 AstraZeneca AB Combination therapy of zd6474 with 5-fu and/or cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
CA2531862C (en) * 2003-07-10 2011-10-25 Astrazenca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
CA2569277A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
EP1804802A2 (en) * 2004-09-27 2007-07-11 AstraZeneca AB Combination comprising zd6474 and an imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
US20080269261A1 (en) * 2005-12-22 2008-10-30 Anderson Joseph Ryan Combination of Zd6474 and Pemetrexed
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398120T1 (de) * 1999-11-05 2008-07-15 Astrazeneca Ab Neue quinazolin-derivate
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
MXPA05001458A (es) * 2002-08-09 2005-06-06 Astrazeneca Ab Combinacion de zd6474, un inhibidor del receptor del factor de crecimiento endotelial vascular, con radioterapia en tratamiento de cancer.
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
EP1592423B1 (en) * 2003-02-13 2011-04-20 AstraZeneca AB Combination therapy of zd6474 with 5-fu and/or cpt-11
CA2531862C (en) * 2003-07-10 2011-10-25 Astrazenca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
EP1804802A2 (en) * 2004-09-27 2007-07-11 AstraZeneca AB Combination comprising zd6474 and an imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
JP4834985B2 (ja) * 2004-12-10 2011-12-14 日産自動車株式会社 組電池の容量調整装置
US20080269261A1 (en) * 2005-12-22 2008-10-30 Anderson Joseph Ryan Combination of Zd6474 and Pemetrexed
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
NO20053649D0 (no) 2005-07-27
EP1592423A2 (en) 2005-11-09
MXPA05008583A (es) 2005-11-04
NO331486B1 (no) 2012-01-16
JP2014065750A (ja) 2014-04-17
WO2004071397A2 (en) 2004-08-26
JP2011016853A (ja) 2011-01-27
HK1084032A1 (en) 2006-07-21
EP1592423B1 (en) 2011-04-20
JP2006517575A (ja) 2006-07-27
CA2514227A1 (en) 2004-08-26
US20110086870A1 (en) 2011-04-14
AU2004212255B2 (en) 2007-07-05
NO20053649L (no) 2005-09-12
WO2004071397A3 (en) 2004-10-14
JP5563950B2 (ja) 2014-07-30
US20100130520A1 (en) 2010-05-27
SI1592423T1 (sl) 2011-07-29
DK1592423T3 (da) 2011-06-27
DE602004032310D1 (de) 2011-06-01
IL169702A (en) 2014-05-28
US20060142316A1 (en) 2006-06-29
KR20110006699A (ko) 2011-01-20
IL169702A0 (en) 2007-07-04
NZ541297A (en) 2008-03-28
CY1111565T1 (el) 2015-10-07
ATE506062T1 (de) 2011-05-15
CA2514227C (en) 2011-08-09
US20120252826A1 (en) 2012-10-04
AU2004212255A1 (en) 2004-08-26
KR20050100683A (ko) 2005-10-19

Similar Documents

Publication Publication Date Title
HK1084032A1 (en) Combination therapy of zd6474 with 5-fu and/or cpt-11
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
EP1971338B8 (en) Combination of zd6474 and pemetrexed
MX2007005356A (es) Terapia de combinacion que comprende zd6474 y un antiadrogenico.
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
ZA200600188B (en) Combination therapy
GB0406445D0 (en) Combination therapy
MXPA05013827A (es) Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.